Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752599 | 0.85 | STAT3 (0.41) | STAT3PLA2G7ALOX15LMNATRPM2 | |
| SCHEMBL31011271 | 0.85 | STAT3 (0.41) | STAT3PLA2G7ALOX15LMNATRPM2 | |
| SCHEMBL25097669 | 0.84 | LMNA (0.43) | STAT3PLA2G7LMNATRPM2TDP1 | |
| SCHEMBL24877854 | 0.83 | STAT3 (0.43) | STAT3PLA2G7ALOX15LMNATRPM2 | |
| SCHEMBL21752547 | 0.81 | TRPM2 (0.45) | STAT3PLA2G7LMNATRPM2TDP1 | |
| SCHEMBL21996096 | 0.81 | LMNA (0.51) | TMEM97LMNATDP1SIGMAR1TSHR | |
| SCHEMBL16006803 | 0.79 | TRPM2 (0.47) | STAT3PLA2G7ALOX15LMNATRPM2 | |
| SCHEMBL20866257 | 0.77 | STAT3 (0.42) | STAT3PLA2G7ALOX15LMNATRPM2 | |
| SCHEMBL25097671 | 0.76 | LMNA (0.46) | STAT3PLA2G7LMNATRPM2TDP1 | |
| SCHEMBL21995891 | 0.74 | ALOX15 (0.41) | ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | STAT3 3316/4885TMEM97 4354/4885PLA2G7 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.